A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort
PHASE1CompletedINTERVENTIONAL
Enrollment
320
Participants
Timeline
Start Date
June 29, 2017
Primary Completion Date
March 26, 2018
Study Completion Date
March 26, 2018
Conditions
Healthy Volunteers
Interventions
DRUG
MA-0211
oral
DRUG
Placebo
oral
Trial Locations (1)
21225
Parexel - Baltimore, Baltimore
All Listed Sponsors
lead
Astellas Pharma Global Development, Inc.
INDUSTRY
NCT03682484 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort | Biotech Hunter | Biotech Hunter